Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Mansi

Showing results (131-140 of 135) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 135 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2005
Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group studyT R Jeffry Evans, Ann Yellowlees, Elizabeth Foster, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2004
A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trialI E Smith, R P A'Hern, G A Coombes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 13, 2012
An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study)R C Coombes, T Tat, M L Miller, et al.
The New England Journal of Medicine|November 3, 2006
Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancerChristopher J Poole, Helena M Earl, Louise Hiller, et al.
British Journal of Cancer|October 11, 2012
Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trialsH M Earl, L Hiller, J A Dunn, et al.
Pageof 14

Showing results (131-140 of 135) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 135 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2005
Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group studyT R Jeffry Evans, Ann Yellowlees, Elizabeth Foster, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2004
A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trialI E Smith, R P A'Hern, G A Coombes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 13, 2012
An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study)R C Coombes, T Tat, M L Miller, et al.
The New England Journal of Medicine|November 3, 2006
Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancerChristopher J Poole, Helena M Earl, Louise Hiller, et al.
British Journal of Cancer|October 11, 2012
Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trialsH M Earl, L Hiller, J A Dunn, et al.
Pageof 14